Meta-analysis of the association between MBD4 Glu346Lys polymorphism and cancer risk.

Abstract

OBJECTIVE:

The purpose of this study was to systematically evaluate the association between methyl-CpG binding domain 4, DNA glycosylase (MBD4) Glu346Lys polymorphism and cancer risk.

METHODS:

A comprehensive document retrieval from the Chinese National Knowledge Infrastructure (CNKI), EMBASE, and PubMed databases was performed through 1 September 2019. The strength of the correlation was assessed using the pooled odds ratio (ORs) and 95% confidence interval (CIs).

RESULTS:

Five relevant studies were retrieved following screening, including 1804 cases and 2193 controls. We found no association between MBD4 Glu346Lys polymorphism and cancer risk under all genetic models. Nevertheless, a subgroup analysis based on country showed a strong association in the Chinese population. Under the recessive model, Chinese individuals with the Lys/Lys genotype had a higher risk of cancer (OR = 1.37, 95% CI = 1.11-1.70).

CONCLUSION:

Analysis of the MBD4 Glu346Lys polymorphism in different populations will help to elucidate the pathogenesis of cancer. The polymorphism can be utilized as a biomarker for cancer susceptibility among Chinese people.

• Authors: Jianguo Wang, Huaxiang Shen, Huijun Liang
• Journal: The Journal of international medical research (J Int Med Res) Pg. 300060519895667 (Dec 31 2019) ISSN: 1473-2300 [Electronic] England
• PMID: 31891275 (Publication Type: Journal Article)